文献速递眼底病与葡萄膜炎

多组学生物学衰老与糖尿病视网膜病变及预期寿命的关联

Associations of Multiomics Biological Aging With Diabetic Retinopathy and Life Expectancy.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

基于英国生物银行68,672名代谢组队列和8,716名蛋白质组队列的糖尿病或糖尿病前期参与者,研究发现代谢组学衰老评分和蛋白质组年龄差(ProtAgeGap)较高与现患和 incident 糖尿病视网膜病变(DR)风险升高相关,且独立于糖化血红蛋白和糖尿病病程;在DR患者中,代谢组学衰老最高四分位与预期寿命降低相关。

要点

  • 代谢组学衰老评分和ProtAgeGap较高均与现患DR风险升高相关。
  • 随访中位13.40年,代谢组学衰老评分与 incident DR 的HR为1.73(95%CI 1.59-1.88),ProtAgeGap的HR为1.12(95%CI 1.07-1.17)。
  • 45岁时DR患者预期寿命低于无DR者,且DR患者中代谢组学衰老最高四分位者预期寿命更低。

核心结论

  • 代谢组学和蛋白质组学生物学衰老加速与糖尿病视网膜病变风险升高相关,尤其在血糖控制差或糖尿病病程长的人群中。
  • 在糖尿病视网膜病变患者中,代谢组学衰老加速与预期寿命降低相关。

研究设计与样本

  • 研究纳入英国生物银行中糖尿病或糖尿病前期参与者,代谢组队列68,672人,蛋白质组队列8,716人。
  • 分别使用代谢组学衰老评分和蛋白质组年龄差(ProtAgeGap)估计生物学年龄。
  • 采用 logistic 回归和 Cox 比例风险模型评估与现患和 incident DR 的关联,并从生存曲线估计预期寿命。

主要发现

  • 横断面分析中,代谢组学衰老评分和ProtAgeGap较高均与现患DR风险升高相关。
  • 前瞻性分析中,中位随访13.40年,代谢组队列中2,491人(3.7%)发生DR,蛋白质组队列中358人(4.14%)发生DR。
  • 代谢组学衰老评分较高与 incident DR 风险升高相关,HR为1.73(95%CI 1.59-1.88);ProtAgeGap较高与 incident DR 风险升高相关,HR为1.12(95%CI 1.07-1.17)。
  • 上述关联独立于糖化血红蛋白水平和糖尿病病程,且与之 additive。
  • 45岁时,DR患者预期寿命低于无DR者;在DR患者中,代谢组学衰老最高四分位者预期寿命低于最低四分位者。

临床怎么用

  • 在糖尿病或糖尿病前期人群中,可关注代谢组学和蛋白质组学生物学衰老标志物以辅助评估DR风险。
  • 对于血糖控制差或糖尿病病程长的患者,生物学衰老加速可能提示更高的DR风险。
  • 对DR患者,代谢组学衰老加速可能提示预期寿命降低,需加强综合管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the associations of omics-based biological aging with diabetic retinopathy (DR) and life expectancy among individuals with DR. METHODS: We included 68,672 UK Biobank participants with prediabetes or diabetes in the metabolomic cohort and 8716 in the proteomic cohort, from which biological age was estimated using a metabolomic aging score and proteomic age (ProtAgeGap), respectively. Associations with prevalent and incident DR were assessed using logistic regression and Cox proportional hazards models, respectively. Life expectancy was estimated from survival curves. RESULTS: Cross-sectionally, both the higher metabolomic aging score and ProtAgeGap were associated with a higher risk of prevalent DR. Prospectively, during a median follow-up of 13.40 years, 2491 participants (3.7%) developed DR among those free of DR at baseline in the metabolomic cohort and 358 (4.14%) in the proteomic cohort. Higher biological aging was associated with increased DR risk, with hazard ratios of 1.73 (95% confidence interval [CI], 1.59-1.88) for the metabolomic aging score and 1.12 (95% CI, 1.07-1.17) for ProtAgeGap. These associations were independent of and additive to glycated hemoglobin levels and diabetes duration. At age 45 years, individuals with DR had reduced life expectancy compared with those without DR. Among those with DR, the highest quartile of metabolomic aging was associated with a reduced life expectancy compared with the lowest quartile. CONCLUSIONS: Advanced metabolomic and proteomic aging were associated with a higher risk of DR, particularly in individuals with poor glycemic control or longer diabetes duration, while advanced metabolomic aging was associated with reduced life expectancy among those with DR.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Yu J, Gao YL, Zhang Y, et al. Associations of Multiomics Biological Aging With Diabetic Retinopathy and Life Expectancy. Invest Ophthalmol Vis Sci. 2026. PMID: 42307181. doi:10.1167/iovs.67.6.36

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。